School of Medicine
Showing 141-160 of 160 Results
-
Takeshi Sugio
Postdoctoral Scholar, Oncology
BioI am a physician-scientist and hematologist focused on clinical translation of T-cell biology. I received my MD from Kyushu University, and subsequently completed Residency Training at Toranomon Hospital, the largest transplant center in Japan. I continued my Hematology training at Kyushu University, where I qualified as a Board-certified specialist (2017) and supervisory hematologist (2021) by the Japanese Society of Hematology. For my PhD (2014-19), I studied expression profiles and histologic features of TCLs. I discovered distinct TCL clinical groups identified by infiltrating immune cell patterns in the microenvironment. Based on my dissertation work (Sugio, et al 2018 Blood Advances), I planned and conducted a Phase II trial of PD1 inhibition for relapsed/refractory TCL (UMIN000034499). I joined the Alizadeh lab at Stanford in 2021, where I am developing tools to analyze immune status using liquid biopsies.
-
Fangdi Sun
Clinical Instructor, Medicine - Oncology
BioDr. Sun is a medical oncologist and clinical investigator at Stanford University. She specializes in the treatment of patients with head and neck malignancies, with specific interests in virus-driven malignancies and novel, biomarker-guided therapies in head and neck cancer. She received her medical degree from Harvard Medical School, followed by a residency and chief residency at the University of California, San Francisco, and then served as chief fellow in hematology and medical oncology at Stanford University. She has earned honors and recognition from the American Association of Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and International Association for the Study of Lung Cancer (IASLC), among other organizations.
-
Melinda L. Telli, M.D.
Professor of Medicine (Oncology)
Current Research and Scholarly InterestsMy research focuses on the development of novel therapies for the treatment of triple-negative and hereditary cancer. Other areas of interest include prevention of cardiac damage associated with breast cancer treatment and cardiotoxicity of anti-cancer agents.
-
Haluk Tezcan, MD
Adjunct Clinical Associate Professor, Medicine - Oncology
BioClinical focus:
Breast Oncology
Molecular Diagnostics
Dr. Tezcan is a medical oncologist and hematologist with over three decades of diverse experience in cancer management and research.
He is leading the clinical development of Droplet Biosciences' novel liquid biopsy technology, a first-in-class lymphatic fluid molecular residual disease assessment, overseeing the scientific and clinical development of the technology. With over three decades of direct patient care and clinical trial experience as a principal investigator and director, both in academia and private practice, he has a firsthand understanding of the unmet clinical needs of physicians and patients, as well as broad experience in clinical trial design and implementation.
He is also co-principal at Athea Oncology, guiding practices and hospitals in developing clinical trial programs and high-value real-world data collection and diagnostic companies in clinical development. He is also a reviewer of JCO Precision Medicine.
Before joining Athea Oncology and Droplet Biosciences, he was the co-founder of LexentBio, which was successfully acquired by Roche/FMI. He also served as Director of Translational Medicine at Genomic Health and as Vice President, leading oncology development at Counsyl, where he integrated science with clinical product development. He established the CA.RE.foundation, a cancer research foundation dedicated to enabling the execution of clinical trials across community oncology sites throughout the Northwest US. He has independently built multiple software tools to help oncologists navigate the practical realities of their daily work. -
Heather Wakelee
Winston Chen and Phyllis Huang Professor
Current Research and Scholarly InterestsDr. Wakelee's research is focused on clinical trials and translational efforts in patients with lung cancer and other thoracic malignancies such as thymoma and thymic carcinoma. Other interests include translation projects in thoracic malignancies and collaborations with population scientists regarding lung cancer questions.
-
Maggie Zhou
Instructor, Medicine - Oncology
BioDr. Zhou is an Instructor in the Division of Oncology at Stanford University with an academic focus in sarcoma. She graduated from Yale University with a B.A. and double majored in economics and molecular, cellular, and developmental biology. She subsequently received her M.D. from Stanford University School of Medicine, where she completed her internal medicine residency and fellowship training.
Her research interests center around the development of novel therapeutics, understanding pathophysiology of rare sarcoma subtypes, and evaluating the utility of circulating tumor DNA for assessing disease response and detecting minimal residual disease. She has co-authored over 20 peer-reviewed publications, including in Clinical Cancer Research and Nature Cell, and is an active member of the Sarcoma Clinical Trial Working Group in the Hoosier Cancer Research Network. Her research has been supported by the Chinese American Hematologist and Oncologist Network and Sarcoma Alliance for Research through Collaboration.
